SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): September 25, 2003
AMERICAN PHARMACEUTICAL PARTNERS, INC.
(Exact name of registrant as specified in its charter)
| Delaware | | 0-31781 | | 68-0389419 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| 11777 San Vicente Boulevard, Suite 550, Los Angeles, California | | 90049 |
| (Address of principal executive offices) | | (Zip Code) |
(310) 826-8505
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report.)
ITEM 5. OTHER EVENTS.
On September 24, 2003, American Pharmaceutical Partners, Inc. (NASDAQ: APPX) issued a press release to announce the preliminary results of a Phase III clinical trial of ABRAXANE™ (ABI-007) in metastatic breast cancer, a copy of which is attached as Exhibit 99.1.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit Number
| | Description
| | | | |
| | | |
| 99.1 | | Press Release dated September 24, 2003. | | | | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| AMERICAN PHARMACEUTICAL PARTNERS, INC. |
| |
By: | | /s/ NICOLE S. WILLIAMS
|
| | | Nicole S. Williams |
| | | Chief Financial Officer |
| | | Date: September 25, 2003 |
